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Early in female mammalian embryonic development, cells randomly inactivate one of the two X chro-
mosomes to achieve overall equal inactivation of parental X-linked alleles. Hcfc1 is a highly conserved
X-linked mouse gene that encodes HCF-1 — a transcriptional co-regulator implicated in cell proliferation
in tissue culture cells. By generating a Cre-recombinase inducible Hcfc1 knock-out (Hcfc1lox) allele in
mice, we have probed the role of HCF-1 in actively proliferating embryonic cells and in cell-cycle re-entry
of resting differentiated adult cells using a liver regeneration model. HCF-1 function is required for both
extraembryonic and embryonic development. In heterozygous Hcfc1lox/þ female embryos, however,
embryonic epiblast-speciﬁc Cre-induced Hcfc1 deletion (creating an Hcfc1epiKO allele) around E5.5 is well
tolerated; it leads to a mixture of HCF-1-positive and -negative epiblast cells owing to random X-chro-
mosome inactivation of the wild-type or Hcfc1epiKO mutant allele. At E6.5 and E7.5, both HCF-1-positive
and -negative epiblast cells proliferate, but gradually by E8.5, HCF-1-negative cells disappear owing to
cell-cycle exit and apoptosis. Although generating a temporary developmental retardation, the loss of
HCF-1-negative cells is tolerated, leading to viable heterozygous offspring with 100% skewed inactivation
of the X-linked Hcfc1epiKO allele. In resting adult liver cells, the requirement for HCF-1 in cell proliferation
was more evident as hepatocytes lacking HCF-1 fail to re-enter the cell cycle and thus to proliferate
during liver regeneration. The survival of the heterozygous Hcfc1epiKO/þ female embryos, even with half
the cells genetically compromised, illustrates the developmental plasticity of the post-implantation
mouse embryo — in this instance, permitting survival of females heterozygous for an X-linked embryonic
lethal allele.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
During animal development a totipotent zygote becomes a
differentiated multicellular organism through regulated patterns
of cell proliferation and differentiation, which themselves are
controlled via programs of gene transcription. Chromatin is the
structural basis by which the genome is packaged and genes are
transcriptionally regulated. Transcriptional regulation involves
physical association between sequence-speciﬁc DNA-binding
proteins and chromatin-modifying enzymes, which in some cases
is aided by protein adaptors that physically link these two classes
of regulators. An example of the latter class is the human herpes
simplex virus host-cell factor HCF-1 (for reviews see Kristie et al.
(2010) and Zargar and Tyagi (2012)).
HCF-1 is a conserved metazoan protein. In mice and human, itInc. This is an open access article u
a Road, Taipei, Taiwan.resides at the transcriptional start sites of many genes (e.g., 743 in
embryonal stem cells and over 5000 in HeLa cells; (Dejosez et al.,
2010; Michaud et al., 2013)) and associates with both sequence-
speciﬁc DNA-binding proteins (e.g., E2F1 and E2F4, Thap11/Ronin,
ZNF143) and chromatin-modifying enzymes (e.g., MLL and Set1
histone H3 Lysine 4 methyltransferases and Sin3 histone deace-
tylase) (for review see Zargar and Tyagi (2012)). Genetic studies in
mammalian cell culture have shown that HCF-1 is important for
multiple aspects of cell proliferation (Goto et al., 1997; Julien and
Herr, 2003; Reilly and Herr, 2002). For example, temperature-
sensitive tsBN67 cells, which carry a point mutation in the ham-
ster gene encoding HCF-1, exit from the cell-division cycle in the
G1 phase when transferred from 33.5 °C to 40 °C — but not im-
mediately, rather after about two rounds of cell division (Goto
et al., 1997).
Here, we study the cell proliferation and developmental roles
of HCF-1 in mice. The mouse gene encoding HCF-1 is called Hcfc1
and resides on the X chromosome (Frattini et al., 1996; Kristie,
1997), and as such is subject to transcriptional silencing viander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mammals occurs in two waves — imprinted followed by random
inactivation: (i) in the imprinted form, soon after fertilization,
there is exclusive inactivation of the paternally inherited X (Xp)
chromosome such that only the maternally inherited X (Xm)
chromosome is active in both embryonic and extraembryonic
tissues; (ii) in the random form, the Xp chromosome is reactivated
around the time of implantation in the embryonic tissue ex-
clusively and either X chromosome is subsequently randomly in-
activated (for reviews, see Augui et al. (2011) and Heard and Dis-
teche (2006)).
In heterozygous cells, random X-chromosome inactivation can
be used to study the activity of wild-type and mutant alleles se-
parately but in side-by-side cells. Here, we used this property,
combined with the generation of a conditional mouse Hcfc1
knock-out allele (Hcfc1cKO), to study the role of HCF-1 in em-
bryonic and extraembryonic as well as adult tissues. The results
reveal essential but differing embryonic and adult roles of HCF-1
in cell proliferation. They illustrate as well high plasticity in post-
implantation development as wild-type embryonic cells can fully
compensate for the loss of proliferative potential in their HCF-1-
negative cohorts.2. Materials and methods
2.1. Mice
All experimental studies have been performed in compliance
with the EU and national legislation rules, as advised by the Le-
manique Animal Facility Network (Resal), concerning ethical con-
siderations of transportation, housing, strain maintenance,
breeding and experimental use of animals.
Mice bearing the Hcfc1 conditional (lox) allele were generated
by Ozgene Pty Ltd. The targeting vector contained a 10 kb genomic
sequence of part of the Hcfc1 gene and its upstream sequence.
Brieﬂy, an 870 bp PCR product containing Hcfc1 exons 2 and 3 and
their ﬂanking intron sequences was ampliﬁed from C57BL/6
genomic DNA and cloned into pPCR. The forward primer was de-
signed to include a loxP site (5′ loxP) for Cre-induced re-
combination and the reverse primer a PacI site for subsequent
cloning. A PGK-Neo-SD-IS cassette ﬂanked by FRT sites containing
a second loxP site (3′ loxP) at the 3′ end was inserted into the PacI
site. For homologous recombination, a 5.2 kb fragment upstream
of exon 2 was inserted before the 5′ loxP site and a 3.9 kb fragment
downstream of exon 3 was inserted after the 3′ loxP site. With this
construct a homologously recombined male C57BL/6 embryonic-
stem cell line was isolated and successfully used to create a mosaic
mouse for successful germ-line transmission. The ofﬁcial name for
the resulting mouse allele is B6-Hcfc1tm1Lwh according to the
guidelines by Mouse Genome Informatics (MGI, The Jackson La-
boratory) but it is referred to here as Hcfc1lox. The Hcfc1lox allele
contains two loxP sites, one in intron 1 and another in intron 3,
and can undergo recombination in the presence of Cre re-
combinase. Cre-recombinase-induced deletion of exons 2 and
3 resulted in splicing of exons 1 and 4 as determined by RNA-se-
quence analysis (see tamoxifen induction below).
Other strains used in this study include wild-type C57BL/6 mice
and C57BL/6 mice carrying the Sox2Cretg (Hayashi et al., 2002),
CAG-EGFPtg (Hadjantonakis et al., 1998), and Alb-Cre-ERT2tg
((Schuler et al., 2004); a gift from Dr. Daniel Metzger, IGBMC
Strasbourg) transgenes.
Females and littermate males were housed four to ﬁve per cage
at 23 °C, with a 12:12 h light–dark cycle and ad libitum access to
water and food.2.2. DNA isolation and genotyping
For genotyping, genomic DNAwas isolated frommouse ear tags
for postnatal mice or entire conceptus for whole embryos as
previously described (Truett et al., 2000). For parafﬁn-embedded
embryo sections, DNA for genotyping was extracted by
(i) preferential scraping of the epiblast region of 3–4 sections with
a surgical blade, (ii) transferring the scraped sections into an ep-
pendorf tube, and (iii) deparafﬁnizing and xylene removal as de-
scribed (Gohar and Mohammadi, 2009). Subsequent DNA extrac-
tion was done as described (Truett et al., 2000). Samples were
used for PCR ampliﬁcation with speciﬁc primer sets using the
KAPA2G Fast HotStart Genotyping PCR Mix (cat no. KK5621). The
annealing was done at 62 °C for 15 s with an extension at 72 °C for
10 s.
Primers for genotyping are listed below.
For HCF-1: p1 (5′-GGAGGAACATGAGCTTTAGG-3′), p2 (5′-CAA-
TAGGCGAGTACCATCACAC-3′), and p3 (5′-GGGAAAGTA-
GACCCACTCTG-3′).
For Cre: Sense (5′-AGGTGTAGAGAAGGCACTTAGC-3′) and Anti-
sense (5′-CTAATCGCCATCTTCCAGCAGG-3′) (Le and Sauer, 2000).
For Y chromosome: Sry-1 (5′-AACAACTGGGCTTTGCACATTG-3′)
and Sry-2 (5′-GTTTATCAGGGTTTCTCTCTAGC-3′) (Steele-Perkins
et al., 2005).
For GFP: oIMR0872 (5′-AAGTTCATCTGCACCACCG-3′) and
oIMR1416 (5′-TCCTTGAAGAAGATGGTGCG-3′).
2.3. Tamoxifen induction
Control Hcfc1lox/þ and test Alb-Cre-ERT2tg ; Hcfc1lox/þ adult
mice (10–14 weeks old) were administered intraperitoneal injec-
tions of 1 mg/mouse tamoxifen [100 μl of 10 mg/ml (1:10 ethanol:
corn oil); Sigma-Aldrich CAS#10540-29-1] four times every 24 h
starting on Day 0. High-throughput RNA-sequence analysis
showed that the tamoxifen-induced hepatic Hcfc1hepKO deletion in
Alb-Cre-ERT2tg; Hcfc1hepKO/þ mice led to splicing of Hcfc1 exon 1 to
exon 4.
2.4. BrdU incorporation
To label embryonic cells in S phase, pregnant mice were in-
jected intraperitoneally with the cell-proliferation marker, 5-bro-
mo-2′-deoxyuridine (BrdU; BD Biosciences, cat. # 550891) to a
ﬁnal concentration of 50 mg/kg body weight, sacriﬁced 6 h post-
injection, and BrdU incorporation revealed by immuno-
ﬂuorescence staining (see below).
2.5. Tissue histology and immunohistochemistry
Intact embryonic day (E) 6.5 to E8.5 embryos were parafﬁn-
embedded and sectioned within their decidua along a sagittal axis
to generate 4 μm thick sections using a microtome (MICROM
HM325). Similarly, parafﬁn-embedded E12.5 embryos, and post-
natal (P) 0 and P5 brain and liver tissue samples were also sliced at
4 μm thickness. Early postnatal and adult brain and liver samples
were cut with the help of a cryostat microtome (MICROM HM550)
to generate 20 μm thick cryo-sections.
Parafﬁn-embedded sections were (i) deparafﬁnized in xylene,
(ii) rehydrated through graded alcohol washes, (iii) rinsed twice
with PBS, (iv) antigen revealed by heating in a 750 W microwave
oven until boiling (approximately 10 min) in citrate buffer (10 mM,
pH 6.0), (v) allowed to slowly cool down at 4 °C, (vi) washed twice
with PBS, and (vii) blocked for 30 min with 2% normal goat serum
(NGS) (Sigma-Aldrich, cat. #G9023) in PBS at room temperature
(RT).
Cryo-sections were (i) dried for 10 min, (ii) ﬁxed for 10 min
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#30525-89-4) at 4 °C, (iii) washed thrice with PBS, (iv) permea-
bilized for 10 min with 0.3% Triton X-100 in PBS, (v) washed thrice
with PBS, and (vi) blocked for 1 h with 2% NGS in PBS at RT.
After blocking, immunohistochemistry of both parafﬁn- and
cryo-sections was performed similarly by (i) incubation of the
slices with speciﬁc primary antibody diluted in 2% NGS overnight
at 4 °C, (ii) three washes with PBS, (iii) incubation with secondary
antibody for 30 min in the dark at RT, (iv) three washes with PBS,
(v) counterstaining with 4′,6-diamidino-2-phenylindole (DAPI)
(Sigma-Aldrich, CAS # 28718-90-3), (vi) two washes with PBS, (vii)
embedding with Mowiol mounting medium (Sigma-Aldrich, CAS #
9002-89-5), and (viii) analyzed using an AxioImager M1 micro-
scope with AxioCam MRm monochrome and AxioCam MRc color
cameras (Carl Zeiss AG, Oberkochen, Germany) and a Zeiss CLSM
710 spectral confocal laser scanning microscope. Images were
processed using AxioVision 4.8.2 (Carl Zeiss AG, Oberkochen,
Germany) and Imaris 8.2 (Bitplane Inc.) software. Im-
munohistochemistry of whole mount embryos was done as de-
scribed previously (Joyner and Wall, 2008).
Primary antibodies used were: rabbit anti-HCF-1 (1:1000, H12,
(Wilson et al., 1993)), rat anti-Ki67 (1:60, eBioscience cat. # 41-
5698), anti-HNF4α (1:100, R&D Systems cat. # PP-H1415-00) and
anti-PCNA (1:50, BD Transduction Laboratories cat. # 610665)
mouse monoclonal antibodies, rabbit anti-Histone H3 phospho
Ser10 (1:100, Abcam cat. # ab5176), rabbit anti-Oct4 (1:250, Ab-
cam cat. # ab19857), and chicken anti-GFP (1:500, Aves Labs, Inc.
cat. # GFP-1020).
Secondary antibodies used were: goat anti-rabbit Alexa 488
(1:400, Molecular Probes cat. # A11034), goat anti-mouse Alexa
568 (1:500, Molecular Probes cat. # A11019), goat anti-rabbit Alexa
568 (1:1000, Molecular Probes cat. # A21069), goat anti-mouse
Alexa 488 (1:400, Molecular Probes cat. # A11029), donkey anti-
mouse Alexa 594 (1:500, Molecular Probes cat. # A11005), and
goat anti-mouse Alexa 635 (1:300, Molecular Probes cat. #
A31575).
2.6. TUNEL assay
Terminal deoxynucleotidyltransferase-mediated dUTP-biotin
nick end labeling (TUNEL) was performed on parafﬁn-embedded
embryo sections with the in situ cell death detection kit (Roche
Applied Science, product # 11684795910), according to the man-
ufacturer directions.
2.7. Partial hepatectomy
2/3 or 70% partial hepatectomy (PH) was performed as de-
scribed (Mitchell and Willenbring, 2008).
2.8. Measurement of body composition by EchoMRI
Total body fat, lean mass, free liquids, and total body water of
live mice were measured with EchoMRI™-100H body composition
analyzer under isoﬂurane anesthesia.
2.9. Quantitation and statistical analyses
For Supplemental Tables 1 and 3, cells in the entire embryonic
region of single 4 mm-thick parafﬁn sections were counted. For
Supplemental Table 4, for each liver studied, all cells in a re-
presentative ﬁeld of a 4 mm-thick parafﬁn section were counted.
Both χ2 tests and Student's t-tests were performed by using the R
package (www.r-project.org).3. Results
3.1. Generation of the Hcfc1cKO allele
Fig. 1A shows a schematic of the wild-type mouse HCF-1 pro-
tein (a), and a description of the genesis of the cKO Hcfc1cKO allele
(b–d) along with its hypothetical truncated HCF-1 product (e). The
mouse Hcfc1 gene consists of 26 exons spread over 25 kb (Fig. 1Ab;
Kristie, 1997). We designed and obtained (see Section 2) a C57BL/6
Hcfc1 allele, called Hcfc1lox, with individual loxP sites ﬂanking
exons 2 and 3 (Fig. 1Ac) for Cre recombinase-mediated exon2/3
deletion generating the Hcfc1cKO allele (Fig. 1Ad). Pre-mRNA spli-
cing of the remaining Hcfc1cKO exons 1 and 4 (see Section 2)
generates an mRNA in which the reading frame goes out of frame
for 2 codons (encoding Gly-Thr) before encountering a termination
codon (Fig. 1Ae). The predicted truncated protein is 66 amino acids
long and unable to make even a single β-stranded blade of the
predicted HCF-1KEL Kelch-domain β-propeller structure (Wilson
et al., 1997) — it is unlikely to possess any wild-type HCF-1
functions.
Fig. 1B shows how we differentiated between the three Hcfc1þ ,
Hcfc1lox and Hcfc1cKO alleles by PCR ampliﬁcation with a mix of the
three oligonucleotide primers p1, p2, and p3 generating three
different ampliﬁcation products: 476, 551 and 347 bp, respectively.
Note that, for the Hcfc1þ and Hcfc1lox alleles, larger p1/p3 ampli-
ﬁcation products of 1053 or 1272 bp, respectively, spanning exons
2 and 3 were not observed under our PCR conditions.
To genotype individuals, as shown in Fig. 1C, we analyzed the
Hcfc1-allele status (top), and the presence or absence of the Cre
transgene (middle) and Y chromosome (bottom). In the absence
(lanes 1 and 2) or presence (lanes 5 and 6) of an active Cre
transgene (here Sox2Cretg; see below), DNA isolated from wild-
type Hcfc1þ male (lanes 1 and 5) or female (lanes 2 and 6) off-
spring resulted in the generation of the wild-type 476 bp (þ)
fragment. In the absence of a Cre transgene, a hemizygous
Hcfc1lox/Y male (lane 3) and heterozygous Hcfc1lox/þ female (lane
4) generated the expected 551 bp loxP-speciﬁc (lox) fragment in
the absence (hemizygous male) or presence (heterozygous female)
of the wild-type 476 bp fragment. The presence of a Cre transgene,
however, resulted in a heterozygous Hcfc1lox/þ female being con-
verted to a heterozygous Hcfc1cKO/þ female that generated the
Hcfc1cKO allele-speciﬁc product of 347 bp (cKO; lane 7). (Note that
there were no Hcfc1cKO/Y male offspring — see below.) The accu-
racy of the Cre recombinase-induced loxP recombination deleting
Hcfc1 exons 2 and 3 was veriﬁed by DNA-sequence analysis (data
not shown).
The availability of mice carrying the Hcfc1lox allele permitted us
to study Hcfc1 function under a number of diverse conditions.
Table 1 describes the terminology for the different Hcfc1 alleles
generated for this study: by using different sources of Cre re-
combinase, we generated the Hcfc1cKO allele under three different
conditions: (i) in the embryonic epiblast in combination with an
autosomal Sox2Cretg transgene (Hayashi et al., 2002, 2003) — we
refer to this allele as Hcfc1epiKO, (ii) in adult liver hepatocytes in
combination with a tamoxifen-inducible Alb-Cre-ERT2tg transgene
(Schuler et al., 2004) — we refer to this allele as Hcfc1hepKO, and
(iii) speciﬁcally on the paternally inherited Xp chromosome (see
below) — we refer to this allele as Hcfc1XpKO. A fourth allele, re-
presenting a maternally inherited X-linked Hcfc1epiKO allele, is
referred to as Hcfc1XmKO.
3.2. Broad Hcfc1 expression in mouse tissues
Before analyzing the effects of Hcfc1 inactivation, we assayed
Hcfc1 expression in the mouse. The human HCFC1 gene is highly
expressed in actively dividing cells in culture and in fetal and
Fig. 1. Generation of an Hcfc1 conditional knockout allele in mice. (A) Schematic representation of the mouse HCF-1 protein and Hcfc1cKO allele generation. (a) HCF-1
elements represent a Kelch domain (HCF-1KEL); basic and acidic regions enriched in basic and acidic residues, respectively; six proteolytic processing repeats (HCF-1PRO); two
ﬁbronectin type 3 repeats (HCF-1Fn3) formed from N- (Fn3n) and C- (Fn3c) terminal segments (Park et al., 2012); and a C-terminal nuclear localization signal (NLS). (b) The
wild-type (wt) murine Hcfc1 allele (þ) consists of 26 exons spanning 25 kb on the X chromosome. (c) The Hcfc1 conditional allele (lox) contains loxP sites before exon 2 and
after exon 3. (d) The presence of Cre protein results in the generation of the conditional knockout (cKO) allele. (e) The cKO allele results in exon 1 to exon 4 splicing, which
predicts the synthesis of a 66 amino acid truncated HCF-1 protein. FRT: residual sequence remaining from removal of the selection marker in embryonic stem cells before
generation of the mice. (B) (a) Wild-type (þ), (b) lox, and (c) cKO Hcfc1 alleles can be distinguished by PCR using the primer pairs (p1, p2, and p3) indicated. Predicted
fragment sizes are indicated. (C) Electrophoretic separation of PCR products of wt Hcfc1þ /Y male (lane 1), wt Hcfc1þ /þ female (lane 2), Hcfc1lox/Y male (lane 3), Hcfc1lox/þ
female (lane 4), Sox2Cretg; Hcfc1þ /Y male (lane 5); Sox2Cretg; Hcfc1þ /þ female (lane 6); and Sox2Cretg; Hcfc1cKO/þ heterozygous female (lane 7) to analyze the Hcfc1-allele
status (top), and the presence or absence of the Cre transgene (middle) or Y chromosome (bottom).
Table 1
Description of Hcfc1 alleles used in this study.
Alleles Description
Hcfc1þ Wild-type
Hcfc1lox Hcfc1 gene containing loxP sites ﬂanking exons 2 and 3 for induced knockout by Cre recombinase
Hcfc1cKO Conditional knock-out of the Hcfc1lox allele by Cre recombinase
Hcfc1epiKO Epiblast-speciﬁc Hcfc1 knockout induced by paternal Ap Sox2Cretg and maternal Xm Hcfc1lox inheritance
Hcfc1hepKO Liver hepatocyte-speciﬁc Hcfc1 knockout by tamoxifen-induced Alb-Cre-ERT2tg and Hcfc1lox inheritance
Hcfc1XpKO Xp-speciﬁc Hcfc1 knockout induced by maternally inherited Cre recombinase resulting from a female Sox2Cretg; Hcfc1epiKO/þ and male Hcfc1lox/Y cross
Hcfc1XmKO Maternally inherited (Xm) Hcfc1epiKO allele
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in adult tissues, comprising mostly quiescent cells, though the
levels are comparatively reduced (Huang et al., 2012; Wilson et al.,
1995). Here, we investigated the levels and subcellular localization
of mouse HCF-1 by immunostaining wt and Hcfc1lox/Y maleembryos and postnatal tissues. HCF-1 was ubiquitous and pre-
dominantly nuclear in (i) Hcfc1lox/Y embryonic day (E) 2.5 and
3.0 blastomeres (Supplemental Fig. 1A and B), (ii) wt and Hcfc1lox/Y
E6.5–E8.5 embryos (Supplemental Figs. 1 and 2C–E), (iii) Hcfc1lox/Y
E9.5 and E12.5 embryos (Supplemental Fig. 3A and B), and (iv)
S. Minocha et al. / Developmental Biology 412 (2016) 1–17 5brain and liver tissue at postnatal day 0 (P0) and from 10-week old
young adults (Supplemental Fig. 3C–F). Consistent with our in-
ability to observe any abnormal phenotype in Hcfc1lox/Y mice (see
below), the staining and localization of HCF-1 were identical in wt
and Hcfc1lox/Y mice (compare Supplemental Figs. 1 and 2). The
broad pattern of Hcfc1 expression suggests that HCF-1 plays roles
in both proliferating and non-proliferating cells.
3.3. Complete embryonic loss of HCF-1 is lethal
Initial crosses between Hcfc1lox mice and the OzCre mouse strain
homozygous for a Cre transgene driven by the PGK promoter (Ozgene,
Perth, Australia) failed to generate progeny carrying the Hcfc1cKO allele.
Given the very early onset of PGK expression during embryonic de-
velopment (McBurney et al., 1994), we asked whether later epiblast-
speciﬁc Hcfc1 deletion might lead to viable offspring, by crossing
heterozygous Sox2Cretg males (tg for transgene) and homozygous
Hcfc1lox/lox females. Sox2Cretg mice carry an autosomal Cre transgene
that, when paternally inherited, directs an onset of Cre recombinase
synthesis around E4.5 exclusively in the post-implantation epiblast
(Hayashi et al., 2002, 2003).Fig. 2. Epiblast-speciﬁc depletion of HCF-1 is evident at E5.5. (A) Immunoﬂuorescence an
male embryos at E5.5. Immunostaining was performed with anti-HCF-1 antibody (green)
all panels. (B) Electrophoretic separation of PCR products of control Hcfc1lox/Y (lane 1) a
(top), and the presence or absence of the Cre transgene (middle) and Y chromosome (bot
(C) Graph showing the percentage of HCF-1-positive cells in control Hcfc1lox/Y (n¼6; baA cross between Hcfc1lox/lox females and heterozygous
Sox2Cretg males will result in both Hcfc1lox/Y male and Hcfc1lox/þ
female zygotes, either with or without the Sox2Cre transgene. Only
Hcfc1lox/Y male zygotes with the Sox2Cretg allele can generate a
complete epiblast-speciﬁc Hcfc1epiKO deletion during embryonic
development; heterozygous Hcfc1lox/þ female zygotes with the
Sox2Cretg allele are instead expected to generate a heterozygotic
epiblast-speciﬁc Hcfc1epiKO deletion.
To test the efﬁcacy and timing of Sox2Cretg-induced Hcfc1lox to
Hcfc1epiKO conversion, we probed, as shown in Fig. 2, E5.5 litter-
mate Hcfc1lox/Y embryos carrying or not the Sox2Cretg transgene
for the presence of the Hcfc1epiKO allele by PCR (Fig. 2B) and HCF-1
protein by immunostaining (Fig. 2A). Already at E5.5, in the pre-
sence of the Sox2Cretg transgene (lane 2, Fig. 2B, middle), the
Hcfc1epiKO allele is evident (lane 2, Fig. 2B, top; red arrowhead);
immunostaining showed that, in contrast to the Hcfc1lox/Y embryo
lacking the Sox2Cretg transgene where all cells are HCF-1 positive,
in the presence of the Sox2Cretg transgene two-thirds of epiblast
cells are already depleted for HCF-1 (Fig. 2C and Supplemental
Table 1). These results are consistent with initiation of the
Sox2Cretg-transgene mediated Hcfc1epiKO allele generation beforealysis of parafﬁn-embedded sections of control Hcfc1lox/Y and Sox2Cretg; Hcfc1epiKO/Y
and DAPI (blue). The square brackets mark the epiblast region. Scale bar: 25 μm for
nd Sox2Cretg; Hcfc1epiKO/Y (lane 2) male embryos to analyze the Hcfc1-allele status
tom). The arrowhead indicates the epiKO allele-speciﬁc cKO PCR product of 347 bp.
r 1) and Sox2Cretg; Hcfc1epiKO/Y (n¼3; bar 2) male embryos at E5.5.
Table 2
Progeny of Hcfc1lox/lox females crossed with heterozygous Sox2Cretg males.
F1 Progeny Number of progeny
obtained at
Original Hcfc1
genotype
Sox2Cre
transgene
Epiblast Cre-medi-
ated Hcfc1 genotype
Birth E12.5
Hcfc1lox/þ  Hcfc1lox/þ 49 11
Hcfc1lox/þ þ Hcfc1epiKO/þ 43 10
Hcfc1lox/Y  Hcfc1lox/Y 51 9
Hcfc1lox/Y þ Hcfc1epiKO/Y 0 10a
Total embryos analyzed 143 40
a Sites of resorption.
S. Minocha et al. / Developmental Biology 412 (2016) 1–176E5.5, giving time for depletion of HCF-1 in the majority of epiblast
cells by E5.5.
As shown in Table 2, we analyzed the Hcfc1þ status of 143
newborn mice of the Hcfc1lox/lox female crossed with heterozygous
Sox2Cretg; Hcfc1þ /Y males by PCR. Hcfc1lox/þ females and Hcfc1lox/Y
males lacking the Sox2Cretg allele were equally well represented
(49 and 51, respectively; p-value 0.8) among the offspring. Among
the offspring carrying the Sox2Cretg allele, however, there were no
Hcfc1lox/Y or Hcfc1epiKO/Y male offspring (p-value 1.61010). This
result could be explained if the Sox2Cretg transgene is 100% efﬁ-
cient at inducing Hcfc1lox to Hcfc1epiKO allele conversion and the
Hcfc1epiKO allele is subsequently lethal in male embryos. To in-
vestigate this possibility, we analyzed embryos from the
Hcfc1lox/lox and heterozygous Sox2Cretg/þ; Hcfc1þ /Y male crosses at
E12.5 in utero. Indeed, Hcfc1epiKO/Y male embryos were found at
resorption sites (Table 2; Supplemental Fig. 4A), indicating em-
bryonic lethality. Isolation of E9.5 embryos by dissection identiﬁed
Hcfc1epiKO/Y embryos that were exceptionally smaller in size and
morphologically abnormal compared to control Hcfc1lox/Y and
Hcfc1lox/þ — and heterozygous Hcfc1epiKO/þ (see below) — litter-
mate embryos (Supplemental Fig. 4B). Thus, epiblast-speciﬁc loss
of Hcfc1 function in males results in an embryonic lethality be-
tween E5.5 (see Fig. 2A) and E9.5 — this lethality is not explored
further here.
In contrast to the male offspring, female offspring listed in
Table 2 carrying the Sox2Cretg allele were obtained in numbers
similar to Sox2Cretg-negative males and females (43 vs 51 and 49;Table 3
The Hcfc1KO allele is lethal when transmitted through the maternally inherited XM chrom
upon fertilization.p-value 0.4 and 0.5, respectively). All of these Sox2Cretg-positive
female offspring were Hcfc1epiKO/þ heterozygotes (compare lanes
6 and 7, Fig. 1C) lacking the Hcfc1lox allele, indicating that here the
Cre recombinase-induced epiblast-speciﬁc deletion of the X-linked
Hcfc1lox allele was completely penetrant. Together these results
indicate that epiblast-speciﬁc Hcfc1epiKO/þ deletion on the ma-
ternal Xm chromosome can be both efﬁcient and non-deleterious
for long-term viability. Indeed the Sox2Cretg; Hcfc1epiKO/þ female
offspring, although exhibiting marginal (albeit signiﬁcant, p-value
o0.05) differences in body length and lean mass (Supplemental
Fig. 5), remained healthy beyond 1 year and were fertile.
3.4. A maternally inherited Hcfc1XmKO allele is lethal
We used the fertile Sox2Cretg; Hcfc1epiKO/þ females to study the
requirements for HCF-1 function early in development, taking
advantage of the differential activation/inactivation of the ma-
ternal Xm and paternal Xp inherited X-chromosomes post fertili-
zation (see Section 1). Table 3 summarizes the results of these
experiments. We performed four different crosses with all possible
combinations of Hcfc1lox/þ and Sox2Cretg; Hcfc1epiKO/þ females,
and Hcfc1þ /Y and Hcfc1lox/Y males. To ensure that embryos defec-
tive in early development would be identiﬁed in the analysis, we
examined and genotyped, in addition to perinatal mice, embryos
at E7.5. As expected, Hcfc1lox/þ females crossed with either
Hcfc1þ /Y or Hcfc1lox/Y males produced an approximate Mendelian
1:1:1:1 ratio of the four possible sex-linked genotypes (data not
shown). In contrast, as shown in Table 3, Sox2Cretg; Hcfc1epiKO/þ
females crossed with either Hcfc1þ /Y (Cross 1) or Hcfc1lox/Y (Cross
2) males gave more complex viability outcomes.
Cross 1 (Sox2Cretg; Hcfc1epiKO/þ Hcfc1þ /Y) tests whether an
Hcfc1KO allele inherited on the Xm chromosome (Hcfc1XmKO; see
Table 1) can give rise to progeny (see Supplemental Table 2 for a
description of the Hcfc1 allele outcomes of Crosses 1 and 2). In-
deed, it cannot as the only normal embryos or pups obtained in
this cross were either Hcfc1þ /Y males or Hcfc1þ /þ females (Ta-
ble 3, columns 1 and 3; p-value 6.7108). Given the Hcfc1epiKO/Y
lethality described in Table 2, the absence of Hcfc1XmKO/Y male
embryos or pups lacking a wild-type Hcfc1þ allele was to be ex-
pected (column 2). Here, however, whereas heterozygous
Hcfc1epiKO/þ embryos and pups were viable in Table 2,osome but not when generated de novo on the paternally inherited XP chromosome
Fig. 3. A maternally inherited Hcfc1þ allele is required very early in development. Immunoﬂuorescence analysis of E7.5 Hcfc1þ /þ and Hcfc1XmKO/þ embryos obtained from
the mating of Sox2Cretg; Hcfc1epiKO/þ female and Hcfc1þ /Y male mice (Cross 1 of Table 3). All sections were stained with DAPI (blue) and anti-HCF-1 antibody (green) together
with antibodies against (A) the epiblast-cell marker Oct4 (red), (B) the cell-proliferation marker Ki67 (red), or (C) the interphase and M-phase marker H3S10P (red).
(D) Sections were stained with TUNEL (red) together with anti-HCF-1 antibody (green) and DAPI (blue). TUNEL-positive apoptotic cells are shown in red. C, conceptus; E,
epiblast. Scale bar: 100 μm.
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were highly abnormal (column 4; see below). These results in-
dicate that the maternal Xm Hcfc1þ allele is required in extra-
embryonic tissue and/or before the epiblast stage of embryonic
development.
To explore the nature of the lethality generated by the maternal
Hcfc1XmKO allele, we immunostained parafﬁn sections of embryos
obtained from Cross 1 at E7.5 as shown in Fig. 3. For this analysis,
we used Oct4 immunoﬂuorescence to distinguish embryonic (Oct4
positive) and extraembryonic (Oct4-negative) tissues (Fig. 3A).
Wild-type embryos (Table 3, columns 1 and 3) revealed HCF-1
staining in both embryonic and extraembryonic (visceral en-
doderm) tissues (Fig. 3A–D, top panels). In wild-type embryos
there was also marked staining for the broad cell-proliferation
marker Ki67 (Scholzen and Gerdes, 2000) (Fig. 3B) and the inter-
phase and mitotic marker histone H3 phosphorylated at serine 10
(H3S10P) (Prigent and Dimitrov, 2003) (Fig. 3C), thus displaying an
active proliferation phenotype. Furthermore, TUNEL assays re-
vealed little apoptosis (Fig. 3D).
In contrast, the highly abnormal Hcfc1XmKO/þ female embryos
(Table 3, column 4), with Xm Hcfc1XmKO and Xp Hcfc1þ alleles,
were signiﬁcantly smaller in size (Fig. 3A–D) than their wild-type
littermate embryos. Consistent with maternal Hcfc1XmKO in-
heritance, HCF-1 immunostaining revealed an absence of HCF-1 in
the extraembryonic region (Fig. 3A–D). The cells in the abnormal
epiblast region (i.e., Oct4 positive; Fig. 3A bottom panel), however,
were essentially all HCF-1 positive (Fig. 3A–D), which must be
owing to an active wild-type paternal Xp Hcfc1þ allele.Nevertheless, although HCF-1 positive, these abnormal embryos
displayed a signiﬁcant reduction in Ki67 and H3S10P labeling and
a high proportion of apoptotic cells when compared to control
embryos (Fig. 3B–D). These results are most easily explained if
HCF-1 function is essential for proper extraembryonic develop-
ment and that thus, in its absence, the extraembryonic tissue
cannot support proper embryonic development.
3.5. An Hcfc1cKO allele on the paternally inherited X in Hcfc1þ /XpKO
heterozygotes is viable
Cross 2 tests the phenotype of Hcfc1 inactivation on the pa-
ternally inherited Xp chromosome at the onset of development.
The outcome of Cross 2 (Sox2Cretg; Hcfc1epiKO/þ Hcfc1lox/Y) is
inﬂuenced by the presence of the Sox2Cretg allele in the mothers,
because the Sox2Cretg allele is expressed in the female germ-line
and the Cre recombinase enzyme thus synthesized in the oocyte is
maternally inherited in the zygote irrespective of the segregation
of the autosomal Sox2Cre transgene (Hayashi et al., 2003; Vincent
and Robertson, 2003). Such maternally inherited Cre recombinase
will result in efﬁcient loxP-site induced recombination throughout
the embryonic and extraembryonic derivatives of the early embryo
(Hayashi et al., 2003; Vincent and Robertson, 2003). Thus, in this
cross, the Xp Hcfc1lox allele is expected to undergo efﬁcient cKO
deletion following fertilization. Consistent with this expectation,
in this cross, the Hcfc1Xplox allele did not survive irrespective of
whether the Sox2Cretg transgene was inherited or not, indicating
that the loxP to cKO conversion was 100% efﬁcient and thus readily
Fig. 4. Generation of Hcfc1XpKO allele on the paternally inherited X chromosome is tolerated. Immunoﬂuorescence analysis of E7.5 Hcfc1þ /Y and Hcfc1þ /XpKO embryos
obtained from the mating of Sox2Cretg; Hcfc1epiKO/þ female and Hcfc1lox/Y male mice (Cross 2 of Table 3). (A) Sections were stained with DAPI (blue) and anti-HCF-1 antibody
(green). (B) High magniﬁcation view of the sections shown in (A) together with immunostaining against the cell-proliferation marker Ki67 (red). (C) Sections were stained
with the interphase and M-phase marker H3S10P (red). (D) Sections were stained with TUNEL (red) and DAPI (blue). E, epiblast. Scale bar: 100 μm.
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Interestingly, although as expected from the results of Cross
1 described above we did not obtain male or female embryos with
the maternally inherited Hcfc1XmKO allele (Table 3, columns 2 and
6; p-value 2.3109), we did obtain, albeit in somewhat lower
numbers, normal female embryos and pups carrying the pater-
nally inherited Hcfc1XpKO allele (column 5, p-value relative to wild-
type Hcfc1þ /Y¼0.15). As shown in Fig. 4, however, the E7.5 em-
bryos were smaller, indicating a transitory developmental re-
tardation (see also below). Comparative HCF-1 immunostaining oflittermate wild-type and heterozygous Hcfc1þ /XpKO female em-
bryos at E7.5 revealed HCF-1 throughout the embryonic and ex-
traembryonic tissue (Fig. 4). Additionally, labeling for Ki67 and
H3S10P (Fig. 4B and C) demonstrated active proliferation and
TUNEL staining (Fig. 4D) demonstrated little cell death throughout,
as in wild-type. Thus, inheritance of the Xm Hcfc1XmKO allele is
lethal but very early Hcfc1XpKO allele generation on the Xp chro-
mosome is tolerated. Together, the results of Crosses 1 and 2 sug-
gest that Hcfc1-gene function is essential for extraembryonic and/
or very early embryonic development. Similar parent-of-origin
Fig. 5. Sox2Cretg; Hcfc1epiKO/þ embryos exhibit progressive loss of HCF-1-negative cells from E5.5 to E8.5. Immunoﬂuorescence analysis of HCF-1 in parafﬁn-embedded
sections of Sox2Cretg; Hcfc1epiKO/þ heterozygous female embryos at (A) E5.5, (B) E6.5, (C) E7.5, and (D) E8.5. Nuclei were stained with DAPI (blue) and HCF-1 antibody (green).
The boxed regions at E5.5, E6.5, E7.5, and E8.5 are shown at higher magniﬁcation in subsequent panels. The arrows indicate HCF-1-negative DAPI-stained nuclei.
(E) Percentage of HCF-1-negative cells from E5.5 to E7.5 (n¼3 for E5.5, n¼8 for E6.5, and n¼8 for E7.5). (*p-value o0.05, ***p-value o0.001). Scale bar: 50 μm.
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viously for essential X-linked genes (Longo et al., 2002; O'Donnell
et al., 2004).
Because an Hcfc1cKO allele could not be transmitted through the
male nor female germ line, this Hcfc1cKO allele cannot be main-
tained by germ-line transmission.
3.6. Hcfc1epiKO allele initially resides on the female active or inactive
X
As aforementioned (see Fig. 1C and Table 2), the Hcfc1lox to
Hcfc1epiKO allele conversion is completely penetrant in Hcfc1epiKO/þ
females; thus, if Hcfc1epiKO/þ females undergo random X-chro-
mosome inactivation, cells should bear either one active Hcfc1þ or
Hcfc1epiKO allele depending on the choice of inactivated X chro-
mosome but not both. The lethality of Hcfc1epiKO/Y males thus
raised the question as to expression of the Hcfc1þ and Hcfc1epiKO
alleles in the cells of Hcfc1epiKO/þ female mice — i.e., could cells
whose active X chromosome carries the Hcfc1epiKO allele exist?
To address this question, as shown in Fig. 5A, we im-
munostained parafﬁn sections of Sox2Cretg; Hcfc1epiKO/þ embryos
at E5.5 at which point we know from their male siblings (Fig. 2)
that they will have undergone Cre recombinase-induced
Hcfc1epiKO-allele conversion. In these embryos, the epiblast was a
mixture of 60–65% HCF-1-positive and 35–40% HCF-1-negative
nuclei (Fig. 5A and E; arrows indicate HCF-1-negative nuclei). The
number of HCF-1-negative nuclei was twofold higher in male E5.5
hemizygous Hcfc1epiKO/Y embryos (65–70%; Fig. 2) than in the fe-
male Hcfc1epiKO/þ embryos (35–40%); this result can be explained
if there is little to no a priori skewing of X-chromosomeinactivation such that roughly half the epiblast cells carry either
the wild-type Hcfc1þ or mutant Hcfc1epiKO allele on the active X
chromosome. This result is consistent with (i) effective Hcfc1epiKO
allele generation at around E4.5 to E5.5 (Fig. 2; Hayashi et al.,
2002), (ii) X-chromosome inactivation during the same period
(Mak et al., 2004; McMahon et al., 1983; Rastan, 1982), and (iii)
relatively rapid depletion by HCF-1 turnover or dilution in pro-
liferating cells.
3.7. HCF-1-positive cells compensate for and replace HCF-1-negative
cells during Hcfc1epiKO/þ female embryonic development
The embryonic lethality of Hcfc1epiKO/Y males (Table 2) suggests
that heterozygous Hcfc1epiKO/þ female embryos that represent a
mixture of HCF-1-positive and -negative cells (Fig. 5A) survive because
cells positive for HCF-1 are able to compensate for those that are
negative for HCF-1. Such compensation could be non-cell autonomous
such that late stage embryos or adults possess both HCF-1-positive
and -negative cells. Alternatively, Hcfc1 function could be required cell
autonomously in which case HCF-1-positive cells must somehow re-
place HCF-1-negative cells. For example, Hcfc1 function may be re-
quired in speciﬁc tissues and only HCF-1-positive cells populate those
tissues; alternatively Hcfc1 function may be universally required such
that HCF-1-negative cells completely disappear.
To discriminate among these possibilities, we assayed the
presence and absence of HCF-1-positive and -negative cells past
E5.5. Fig. 5 shows the results of the analysis of stages E6.5 (Fig. 5B),
E7.5 (Fig. 5C), and E8.5 (Fig. 5D), with quantitation shown in Fig. 5E
for E5.5 through E7.5. Indeed, from E6.5 to E7.5, HCF-1-negative
cells continued to persist (Fig. 5B and C, see white arrows) but
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and 10% (E7.5) of the total embryonic cells (Fig. 5E), such that by
E8.5 HCF-1-negative cells had essentially disappeared (Fig. 5D, see
arrow) to a single evident HCF-1-negative cell. These results sug-
gest that HCF-1 function is essential and cell autonomous, such
that HCF-1-positive cells broadly and progressively replace and
compensate for HCF-1-negative cells during a period of embry-
ogenesis that encompasses gastrulation, a process key in the in-
itiation of tissue differentiation.
The observed mixed population of HCF-1-positive and -negative
cells early in embryogenesis followed by an eventual dominance of
HCF-1-positive cells later in embryogenesis is most easily explained if
cells carrying the Hcfc1þ allele on the active X chromosome are po-
sitively selected during Hcfc1epiKO/þ embryogenesis. To address this
hypothesis directly, we employed an X chromosome marked with aFig. 6. Hcfc1epiKO/þ; XGFPtg embryos exhibit progressive gain of Hcfc1þ-linked X-chro
obtained from mating Hcfc1þ /Y male mice carrying Sox2Cretg and XGFPtg alleles with Hc
allele on the same chromosome, and Hcfc1lox or Hcfc1epiKO allele on the other. The proge
were stained with DAPI (blue) and anti-GFP (green) antibodies. The boxed regions in (G
shown at higher magniﬁcation in the panels in the row below. Scale bar: 25 μm.green ﬂuorescent protein transgene called XGFP (Hadjantonakis et al.,
2001, 1998); cells carrying the XGFPtg transgene will immunostain for
GFP only when the XGFP allele is active thus allowing the determi-
nation of which X chromosome is active. We crossed Hcfc1þ /Y male
mice carrying the Sox2Cretg and XGFPtg transgenes with Hcfc1lox/lox
females. Female offspring will carry an Xp XGFPtg chromosome linked
to the wild-type Hcfc1þ allele, and either an Hcfc1lox or— eventually—
Hcfc1epiKO allele on the Xm chromosome depending on the absence or
presence of the Sox2Cretg transgene, respectively. In contrast, male
offspring cannot carry the Xp XGFPtg chromosome.
The results of this experiment are shown in Fig. 6, with GFP
levels analyzed by whole-mount GFP immunostaining. As ex-
pected, the Hcfc1lox/Y male embryos did not display speciﬁc GFP
staining at any stage (Fig. 6A, D, and G). In contrast, both E6.5
Hcfc1lox/þ and Hcfc1epiKO/þ XGFPtg embryos displayed a mottledmosome expression from E6.5 to E8.5. Immunoﬂuorescence analysis of embryos
fc1lox/lox female mice. Female offspring carry the XGFPtg transgene and the Hcfc1þ
ny were collected at E6.5 (A–C), E7.5 (D–F), and E8.5 (G–I). Whole mount embryos
) Hcfc1lox/Y, (H) Hcfc1lox/þ; XGFPtg, and (I) Hcfc1epiKO/þ; XGFPtg embryos at E8.5 are
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activation of the XGFPtg chromosome. In concordance with the
disappearance of HCF-1-negative cells in Hcfc1epiKO/þ embryos,
over the next two days of development, the percentage of GFP-
positive cells (carrying the active wild-type Hcf1þ allele) increased
such that, throughout the entire embryo, we failed to observe
tissues with GFP-negative cells (compare Fig. 6E and F, and H and
I). We also similarly assayed GFP — as well as HCF-1 — levels in the
eye later in embryonic development (i.e., E14.5; Supplemental
Fig. 6) and in early postnatal (P5) brain and liver (Supplemental
Fig. 7) and similarly observed a broad, essentially universal, pre-
sence of GFP and HCF-1 in the Hcfc1epiKO/þ; XGFPtg but not
Hcfc1lox/þ ; XGFPtg mice.
These results suggest an early universal strong selection for the
Hcfc1þ allele on the active X chromosome (i.e., HCF-1-positiveFig. 7. HCF-1-negative cells can proliferate at E6.5. Immunoﬂuorescence analysis of para
E6.5. All sections were stained with DAPI (blue) and anti-HCF-1 antibody (green) together
marker BrdU following 6 h BrdU incorporation (red), or (C) the interphase and M-phase
DAPI (blue) and anti-HCF-1 antibody (green). TUNEL-positive apoptotic cells are shown i
point to a few HCF-1-positive nuclei. Scale bar: 50 μm.cells) leading to 100% selection of cells carrying the
Hcfc1epiKO-allele on the inactive X-chromosome — a so-called
complete secondary skewing of X-chromosome inactivation. This
skewing by which HCF-1-positive cells compensate for HCF-1-
negative cells is apparently effective: although Hcfc1epiKO/þ em-
bryos are reduced in size and developmentally retarded between
E6.5 and at least E8.5 (Supplemental Fig. 8A–C) — owing to an
apparent subsequent acceleration in development and growth —
this reduction is largely transient as, for example, E9.5 (Supple-
mental Fig. 4B) and E14.5 (Supplemental Fig. 8D) Hcfc1lox/þ and
Hcfc1epiKO/þ embryos are of similar size. Combined with the high
frequency of Hcfc1epiKO/þ heterozygous pup births (Table 2), the
Hcfc1epiKO/þ developmental proﬁle indicates that the replacement
of HCF-1-negative cells by the HCF-1-positive ones in Hcfc1epiKO/þ
embryos is highly effective to maintain viability.fﬁn-embedded sections of Sox2Cretg; Hcfc1epiKO/þ heterozygous female embryos at
with antibodies against (A) the cell-proliferation marker Ki67 (red), (B) the S-phase
marker H3S10P (red). (D) TUNEL assay was performed on sections co-stained with
n red. In A–D, the white arrows point to HCF-1-negative nuclei and magenta arrows
S. Minocha et al. / Developmental Biology 412 (2016) 1–17123.8. HCF-1-negative cells proliferate in E6.5 embryos
Hcfc1 is implicated in cell proliferation (Goto et al., 1997; Julien
and Herr, 2003). Thus, the presence in Fig. 5 of large numbers of
HCF-1-negative cells in E6.5 embryos one to two days after
Hcfc1lox to Hcfc1epiKO conversion was surprising. We hypothesized
that at E6.5 after Hcfc1lox to Hcfc1epiKO conversion HCF-1-negative
embryonic cells might still proliferate. To test this hypothesis we
co-stained E6.5 Hcfc1epiKO/þ embryos for HCF-1 and three cell-
cycle markers: Ki67, the S-phase marker BrdU, and H3S10P. As
shown in Fig. 7 and quantitated in Fig. 9A (see also Supplemental
Table 3), E6.5 HCF-1-negative cells (white arrows) are frequently
positive for Ki67 (Fig. 7A), BrdU incorporation (Fig. 7B), and
H3S10P (Fig. 7C), indicating that indeed HCF-1-negative cells
continue to proliferate.
Nevertheless, eventually the HCF-1-negative cells disappear.
Consistent with this observation, (i) at E7.5 we observe many HCF-
1-negative — but not HCF-1-positive — cells missing the Ki67 cell-
proliferation marker (Figs. 8A and 9B), and (ii), as evidenced by
TUNEL assays (Figs. 7D and 8B and quantitated in Fig. 9), E6.5 and
E7.5 HCF-1-negative — but not HCF-1-positive — cells undergo
apoptosis. Thus continued proliferation of HCF-1-negative cells
appears to lead to cell-cycle exit and eventual apoptosis and
disappearance.
3.9. HCF-1 is crucial for proliferation during liver regeneration
The requirement for HCF-1 in mammalian cell proliferation has
been established in tissue culture cells, but not in an in vivo
physiological context. The continued proliferation of HCF-1-deﬁ-
cient cells observed here during early embryogenesis does not
reveal an immediate essential HCF-1 function in embryonic cell
proliferation. We thus also addressed a role for HCF-1 in cellFig. 8. At E7.5, Hcfc1epiKO/þ HCF-1-negative cells display divergent phenotypes — prol
embedded sections of Sox2Cretg; Hcfc1epiKO/þ heterozygous female embryos at E7.5. (A)
antibodies. The white arrows identify HCF-1-negative nuclei that are Ki67 negative. The
assay was performed on a section co-stained with DAPI (blue) and anti-HCF-1 antibody
HCF-1-negative nuclei that are TUNEL positive. Scale bar: 50 μm.proliferation in a non-embryonic context, by taking advantage of
the high regenerative potential of the mammalian liver. After two-
thirds partial hepatectomy (PH), remaining resting hepatocytes
rapidly and synchronously re-enter the cell-division cycle to re-
generate the liver mass within one to two weeks (Fausto et al.,
2006; Michalopoulos and DeFrances, 1997; Taub, 2004). We uti-
lized this regenerative ability of the liver to study HCF-1 function
in de novo cell-proliferation entry and progression by resting cells.
For this purpose, we induced hepatocyte-speciﬁc deletion of the
Hcfc1lox allele (called Hcfc1hepKO, see Table 1) by tamoxifen activa-
tion of an Albumin-Cre (Alb-Cre-ERT2tg) allele (Schuler et al., 2004)
in 10–14 week-old Alb-Cre-ERT2tg; Hcfc1lox/Y males and Alb-Cre-
ERT2tg; Hcfc1lox/þ females, thus generating knockout Hcfc1hepKO/Y
and heterozygous Hcfc1hepKO/þ hepatocytes, respectively. Prior to
tamoxifen treatment, all Alb-Cre-ERT2tg; Hcfc1lox/þ hepatocytes and
non-hepatocytes — identiﬁed as hepatocyte nuclear factor α
(HNF4α)-positive (green arrows in Fig. 10B) and -negative (mauve
arrows) cells, respectively — are positive for HCF-1 (Fig. 10A and B),
indicating that the Cre-ERT2 recombinase activity is strongly
tamoxifen dependent. Post-tamoxifen treatment, immunoblot
analysis of Alb-Cre-ERT2tg; Hcfc1lox/Y males demonstrated pro-
gressive and signiﬁcant loss of HCF-1 protein (Supplemental Fig. 9),
consistent with activated Alb-Cre-ERT2tg-induced Hcfc1lox to
Hcfc1hepKO allele conversion. Since the expression of Alb-Cre-ERT2tg
transgene is hepatocyte-speciﬁc, presence of some HCF-1 protein
could be still seen at the end of ﬁfth day owing to non-hepatocytes
that are not affected.
In, however, Alb-Cre-ERT2tg; Hcfc1lox/þ females seven days post-
tamoxifen treatment (Fig. 10C and D), whereas smaller HNF4α-ne-
gative non-hepatocyte liver cell types remain HCF-1 positive (mauve
arrow, Fig. 10D), patches of HNF4α-positive hepatocytes either HCF-
1-positive (green arrow, Fig. 10D) or HCF-1-negative (white arrow
and dashed line ovals, Fig. 10D) appear. The HCF-1-negative clustersiferative, non-proliferative or apoptotic. Immunoﬂuorescence analysis of parafﬁn-
The section was stained with DAPI (blue), anti-HCF-1 (green), and anti-Ki67 (red)
magenta arrows identify HCF-1-negative nuclei that are Ki67 positive. (B) TUNEL
(green). TUNEL-positive apoptotic cells are shown in red. The white arrows identify
Fig. 9. Transient proliferation of HCF-1-negative cells is eventually followed by apoptosis. Quantiﬁcation of the data presented in Figs. 7 and 8. (A) Graph showing the
percentages of HCF-1-positive (black) and HCF-1-negative (gray) cells positive for labeling for BrdU, H3S10P, Ki67 or TUNEL in sections of Sox2Cretg; Hcfc1epiKO/þ hetero-
zygous female embryos at E6.5. The difference between percentages of HCF-1-positive and HCF-1-negative cells also positive for BrdU (p-value 0.08) was not signiﬁcant
(n¼4). The differences between percentages of HCF-1-positive and HCF-1-negative cells also positive for H3S10P (p-value 0.02; n¼2), Ki67 (p-value 0.002; n¼5), and TUNEL
(p-value 3.1105; n¼4) were signiﬁcant. (B) Graph showing the percentages of HCF-1-positive (black) and HCF-1-negative (gray) cells positive for labeling for Ki67 or
TUNEL in sections of Sox2Cretg; Hcfc1epiKO/þ heterozygous female embryos at E7.5. The difference between percentages of HCF-1-positive and HCF-1-negative cells also
positive for Ki67 (p-value 5104; n¼5) and TUNEL (p-value 7104; n¼6) were highly signiﬁcant.
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genitor cells in which the Hcfc1lox allele was on the active X chro-
mosome and the HCF-1-positive clusters are probably owing toFig. 10. Hepatocyte-speciﬁc Hcfc1hepKO allele generation in Alb-Cre-ERT2tg; Hcfc1lox/þ mi
(A and B) Alb-Cre-ERT2tg; Hcfc1lox/þ control and (C and D) 7-day post-tamoxifen treatme
DAPI (blue), and anti-HCF-1 (green) and hepatocyte-speciﬁc anti-HNF4α (red) antibodie
the panels B and D, respectively. Tamoxifen induction generates the Hcfc1hepKO allele as
(broken oval lines) of hepatocytes (C and D). Green arrows point to HCF-1-positive and
negative non-hepatocytes; and white arrow points to an HCF-1-negative and HNF4α-poclones of cells descendent from single progenitor cells in which the
Hcfc1lox allele was on the inactive X chromosome.
Seven days post-tamoxifen treatment of Alb-Cre-ERT2tg;ce. Immunoﬂuorescence analysis of HCF-1 in parafﬁn-embedded liver sections from
nt Alb-Cre-ERT2tg; Hcfc1hepKO/þ 10- week old mice. The sections were stained with
s. The boxed regions in A and C mark the regions shown at higher magniﬁcation in
demonstrated by the 7-day post-treatment loss of HCF-1 protein in speciﬁc clusters
HNF4α-positive hepatocytes; purple arrows point to HCF-1-positive and HNF4α-
sitive hepatocyte. Scale bar: 50 μm.
Fig. 11. Hepatocytes lacking HCF-1 fail cell-division cycle entry upon partial hepatectomy. Immunoﬂuorescence analysis of cell-cycle progression markers of 10-week old
Alb-Cre-ERT2tg; Hcfc1hepKO/þ heterozygous female mice 7 days post-tamoxifen treatment before and 48 h after being subjected to 70% PH. The parafﬁn-embedded sections of
livers before (A, C, and E) and 48 h after (B, D, and F) PH were stained with DAPI (blue), anti-HCF-1 (green), and one of three cell-proliferation markers shown in red: (A and
B) Ki67, (C and D) PCNA, and (E and F) H3S10P. The broken lines in B, D, and F separate the HCF-1-positive from HCF-1-negative hepatocytes. The green arrows point to DAPI-,
HCF-1- and cell-proliferation marker-positive hepatocytes, and the white arrows point to DAPI-positive, HCF-1-negative and cell-proliferation marker-negative hepatocytes.
Scale bar: 50 μm.
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48 h later — at which point hepatocytes are actively passing
through the cell-division cycle — for (i) Ki-67 (Fig. 11B), (ii) the
S-phase marker Proliferating Cell Nuclear Antigen (PCNA)
(Fig. 11D), which displays evident S-phase nuclear staining (Kel-
man, 1997), and (iii) H3S10P (Fig. 11F). Prior to PH, few if any ta-
moxifen-induced Hcfc1hepKO/þ hepatocytes were positive for any
of these three cell-proliferation makers (Fig. 11A, C, and E); 48 h
post-PH, however, many cells were positive for these threemarkers (Fig. 11B, D, and F) but only in the patches of HCF-1-po-
sitive hepatocytes (green arrows) — hepatocytes lacking HCF-1
(white arrows) were negative for the three cell cycle markers (see
also Supplemental Fig. 10), indicating that HCF-1 is required for
proper hepatocyte proliferation during liver regeneration and thus
important for cell-cycle re-entry by these resting cells. Quantita-
tive analysis of the results shown in Fig. 12 (see also Supplemental
Table 4) reinforces this conclusion.
Fig. 12. Only HCF-1-positive cells enter into cell-division cycle upon partial hepatectomy. Quantiﬁcation of the data presented in Fig. 11. Boxplots showing the percentage of
HCF-1-positive (HCF-1þ) and HCF-1-negative (HCF-1) cells positive for labeling for (A) Ki67 (n¼3 prePH; n¼5 postPH) (p-value 1.9105), (B) PCNA (n¼4 prePH; n¼3
postPH) (p-value 6.6.103), and (C) H3S10P (n¼4 prePH; n¼4 postPH) (p-value 9.0104) in sections of Alb-Cre-ERT2tg; Hcfc1hepKO/þ heterozygous female mice 7 days
post-tamoxifen treatment before (prePH) and 48 h after (postPH) being subjected to 70% PH.
S. Minocha et al. / Developmental Biology 412 (2016) 1–17 154. Discussion
We have generated a silent allele of the mouse Hcfc1 gene,
called Hcfc1lox, that can be conditionally deleted with Cre re-
combinase. We take advantage of the broad expression and
X-chromosome linkage of the Hcfc1 gene to study its role in em-
bryonic and extraembryonic development, and adult tissue re-
generation. An unexpected by-product of the X chromosome
linkage of the Hcfc1 gene and the cell-autonomous requirement
for HCF-1 in early embryonic-cell viability is the ability to ge-
netically address the sensitivity of the early post-implantation
embryo to major cell loss.
4.1. HCF-1 has extensive roles in cell proliferation
Our studies show that HCF-1 is important for both embryonic and
extraembryonic mammalian development and illuminate its role in
cell proliferation in two very different contexts: the post-implantation
embryo and the adult regenerating liver. Signiﬁcantly, these two
contexts differ in the status of the cells in which HCF-1 is being de-
pleted — in the embryonic cells HCF-1 is being depleted in pro-
liferating cells whereas in the adult liver HCF-1 is being depleted in
resting cells — and the effects differ. In the embryonic cells, although
eventually having an effect, depletion of HCF-1 does not have an ap-
parent immediate cell-proliferation arrest effect. This phenotype is
reminiscent of the temperature-sensitive tsBN67 hamster cell line, in
which cells continue to proliferate after shift to the non-permissive
temperature (Goto et al., 1997).
In the case of the Hcfc1epiKO/þ embryos, the delay in loss of
HCF-1-negative cells may be owing to a period post Hcfc1epiKO
induction in which, as examples, (i) it takes time for levels of HCF-
1 (an abundant and stable protein; (Wilson et al., 1995; Wysocka
et al., 2001)) to fall below the amount necessary to support cell
proliferation (a level not being easily detected by our immuno-
ﬂuorescence analyses), (ii) loss of HCF-1 transcriptional regulatory
function does not have an immediate effect on transcription of its
regulatory targets (e.g., it could activate histone modiﬁcations that
are maintained for some cell generations via an HCF-1-in-
dependent mechanism), or (iii) HCF-1 is not required for cell
proliferation at the time of epiblast-speciﬁc inactivation.
Vis-à-vis the latter example, the ability of E6.5 HCF-1-negative
cells to proliferate may be related to the rapid proliferation status
of these cells where negative regulators of the cell-division cycle
such as the pRb-related pocket protein family are apparently in-
active (reviewed in Ciemerych and Sicinski (2005)). Indeed, in-
hibition of pRb-related pocket protein family function cansuppress the need for HCF-1 function in cell proliferation (Reilly
et al., 2002) — E6.5 cells may represent such cells with suppressed
pRb-related pocket protein family function.
In contrast, the essentially complete sensitivity of hepatocyte
proliferation to HCF-1 depletion upon PH-induced liver re-
generation may be explained by the fact that, in the liver re-
generation protocol, it is possible to deplete resting hepatocytes
over seven days before challenging them to proliferate de novo
and HCF-1 is essential for de novo hepatocyte proliferation where
the pRb-related pocket protein family is likely active.
4.2. HCF-1 plays early roles in embryonic cell proliferation
The generation of the epiblast-speciﬁc Hcfc1epiKO allele with the
Sox2Cre transgene permits the study of HCF-1 function at an early
stage of embryonic development — around E5.5 and beyond.
Furthermore, as shown in Table 3, we did not observe any embryos
that would have lacked HCF-1 from conception (i.e., Hcfc1XmKO/Y
and Hcfc1XmKO/XpKO embryos), suggesting that HCF-1 plays a role in
cell proliferation even before implantation. Consistent with this
hypothesis, HCF-1 plays a positive role in embryonic stem-cell
proliferation (Dejosez et al., 2010).
Even if only required after E7.5, few cell proliferation genes are
required so early in development (Ciemerych and Sicinski, 2005). This
very early requirement for Hcfc1 function could be because in verte-
brates it is a member of a small gene family consisting of only two
genes — Hcfc1 and the much smaller HCF-2-encoding Hcfc2 (Johnson
et al., 1999) gene — such that there is little possibility for redundant
gene functions. Additionally, HCF-1 associates with large numbers of
transcriptional start sites in both embryonic-stem cells (743) and
transformed HeLa cells (5400) (Dejosez et al., 2010; Michaud et al.,
2013). Such potentially broad involvement in transcriptional regula-
tion could explain an early essential role for HCF-1 in embryogenesis.
4.3. Development of the mouse post-implantation embryo is highly
resistant to cell loss
Animal development involves cell proliferation in which cells
become increasingly committed to particular developmental or
differentiation pathways. The timing of such commitment and its
sensitivity to perturbation varies among species. For example, in
the deterministic development of the Caenorhabditis elegansworm
embryo, differentiation commitment occurs during the ﬁrst cell
divisions and embryonic development is exquisitely sensitive to
individual cell loss (Sulston et al., 1983). By contrast, early mam-
malian embryonic development is much less deterministic and
S. Minocha et al. / Developmental Biology 412 (2016) 1–1716there is considerable plasticity in cell differentiation commitment,
particularly prior to implantation (Martinez Arias et al., 2013). For
example, embryonic cell-depletion experiments pre-implantation
— either micromanipulation to remove one or two cells from two-
to-four cell embryos (Power and Tam, 1993; Rands, 1986) or
pharmacological intervention of 16–32 cell morula-stage embryos
(Tam, 1988) — have shown eventual normal development post cell
depletion.
Post-implantation, however — for example, during gastrulation
which occurs at E6.5 to E7.5 — there is a rapid determination of
cell differentiation pathways (e.g., the three germ layers). This
progressive determination means that, as development pro-
gresses, cells will have followed a greater number of differentia-
tion pathways and functional replacement to compensate for cell
loss may become more difﬁcult. Nevertheless, one study has
shown that treatment of embryos at E6.5 to E7.0 with the cytotoxic
drug mitomycin C can lead to a rapid 85% reduction in cell number
and, in response, to an accelerated cell proliferation response, such
that embryos recover in size and developmental stage by ap-
proximately E10.5 (Snow and Tam, 1979).
Here, by virtue of (i) an early embryonic cell-proliferation re-
quirement for HCF-1 function, (ii) the X-chromosome linkage of
the Hcfc1 gene, and (iii) the creation of a Cre-inducible cKO
Hcfc1lox allele, we have probed through genetic manipulation, ra-
ther than pharmacological intervention, the resistance of the post-
implantation mouse embryo to progressive cell loss beginning
before and ending after gastrulation. In this case, although the
lethality of Hcfc1epiKO/Y male embryos would suggest otherwise,
the progressive loss of HCF-1-negative cells in Hcfc1epiKO/þ female
heterozygotes may be owing to cell competition, whereby HCF-1-
negative cells are not inherently unable to proliferate but instead
they are out-competed by the HCF-1-positive cells. Whether by a
competitive or a non-competitive mechanism, this genetically
engineered post-implantation loss of HCF-1-negative cells had
little effect on developmental success even as the embryos un-
derwent gastrulation, a critical phase of development. In this case,
survival may be aided by the extensive salt and pepper pattern of
HCF-1 loss such that all parts of the embryo have plenty of HCF-1-
positive cells with which to compensate for cells lacking HCF-1.
Whatever the case, our results show that mammalian embryonic
plasticity permits the survival of female embryos heterozygous for
an X-linked embryonic lethal allele.Competing interest statement
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